OTC Markets OTCPK - Delayed Quote USD

Revenio Group Oyj (REVXF)

27.85
0.00
(0.00%)
At close: May 9 at 4:00:00 PM EDT
Loading Chart for REVXF
  • Previous Close 0.00
  • Open 38.89
  • Bid 29.01 x 34100
  • Ask 34.01 x 1000
  • Day's Range 38.89 - 38.89
  • 52 Week Range 27.85 - 38.89
  • Volume 100
  • Avg. Volume 0
  • Market Cap (intraday) 746.419M
  • Beta (5Y Monthly) 1.49
  • PE Ratio (TTM) 36.64
  • EPS (TTM) 0.76
  • Earnings Date Aug 7, 2025
  • Forward Dividend & Yield 0.40 (1.45%)
  • Ex-Dividend Date Apr 11, 2025
  • 1y Target Est --

Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Probes that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used for measuring IOP on animal patients by general veterinary practitioners, veterinary ophthalmologists and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON, a device with confocal retinal imaging; iCare DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. In addition, the company offers iCare ILLUME, a screening software that helps to detect the early signs of diabetic retinopathy, age-related macular degeneration, and glaucoma using artificial intelligence; iCare CLINIC cloud software to store long-term IOP data; and Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.

www.reveniogroup.fi

246

Full Time Employees

December 31

Fiscal Year Ends

Recent News: REVXF

View More

Performance Overview: REVXF

Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is OMX Helsinki_PI (^OMXHPI) .

YTD Return

REVXF
1.46%
OMX Helsinki_PI (^OMXHPI)
0.00%

1-Year Return

REVXF
0.33%
OMX Helsinki_PI (^OMXHPI)
0.00%

3-Year Return

REVXF
61.75%
OMX Helsinki_PI (^OMXHPI)
0.00%

5-Year Return

REVXF
12.55%
OMX Helsinki_PI (^OMXHPI)
0.00%

Compare To: REVXF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: REVXF

View More

Valuation Measures

Annual
As of 5/9/2025
  • Market Cap

    835.71M

  • Enterprise Value

    813.49M

  • Trailing P/E

    36.79

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.57

  • Price/Book (mrq)

    6.30

  • Enterprise Value/Revenue

    6.52

  • Enterprise Value/EBITDA

    22.12

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.96%

  • Return on Assets (ttm)

    12.10%

  • Return on Equity (ttm)

    17.72%

  • Revenue (ttm)

    106.32M

  • Net Income Avi to Common (ttm)

    19.1M

  • Diluted EPS (ttm)

    0.76

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    22.2M

  • Total Debt/Equity (mrq)

    11.34%

  • Levered Free Cash Flow (ttm)

    16.01M

Research Analysis: REVXF

View More

Company Insights: REVXF

Research Reports: REVXF

View More

People Also Watch